CTLA-4 Regulates Induction of Anergy In Vivo

Slides:



Advertisements
Similar presentations
Volume 141, Issue 2, Pages e2 (August 2011)
Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 33, Issue 3, Pages (September 2010)
Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD)  Fumi Miyagawa,
Volume 26, Issue 3, Pages (March 2007)
Feedback Regulation of Pathogen-Specific T Cell Priming
Inhibition of Th1 Differentiation by IL-6 Is Mediated by SOCS1
Volume 31, Issue 2, Pages (August 2009)
Volume 13, Issue 1, Pages (July 2000)
Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell Apoptosis
Volume 141, Issue 2, Pages e2 (August 2011)
Functional Flexibility in T Cells
Volume 30, Issue 4, Pages (April 2009)
Volume 18, Issue 5, Pages (May 2003)
Volume 32, Issue 5, Pages (May 2010)
Ananda W Goldrath, Michael J Bevan  Immunity 
Volume 6, Issue 4, Pages (April 1997)
NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells  Lucie Beaudoin, Véronique.
Volume 15, Issue 6, Pages (December 2001)
Volume 25, Issue 3, Pages (September 2006)
Volume 33, Issue 3, Pages (September 2010)
Volume 6, Issue 5, Pages (May 1997)
Protective Capacity of Memory CD8+ T Cells Is Dictated by Antigen Exposure History and Nature of the Infection  Jeffrey C. Nolz, John T. Harty  Immunity 
Volume 24, Issue 5, Pages (May 2006)
Down-Regulation of IL-4 Gene Transcription and Control of Th2 Cell Differentiation by a Mechanism Involving NFAT1  Alexander Kiani, João P.B Viola, Andrew.
Cell-to-Cell Transfer of M
A Two-Step Process for Thymic Regulatory T Cell Development
Elevation of Intracellular Cyclic AMP in Alloreactive CD4+ T Cells Induces Alloantigen- Specific Tolerance That Can Prevent GVHD Lethality In Vivo  Matthew.
Volume 29, Issue 6, Pages (December 2008)
Volume 28, Issue 5, Pages (May 2008)
C5a Negatively Regulates Toll-like Receptor 4-Induced Immune Responses
Volume 33, Issue 4, Pages (October 2010)
Volume 33, Issue 6, Pages (December 2010)
Volume 33, Issue 3, Pages (September 2010)
Volume 135, Issue 3, Pages (September 2008)
Volume 9, Issue 5, Pages (November 1998)
Andrew T Miller, Heather M Wilcox, Zhongbin Lai, Leslie J Berg 
Volume 119, Issue 1, Pages (July 2000)
Volume 15, Issue 3, Pages (September 2001)
Volume 29, Issue 1, Pages (July 2008)
Volume 17, Issue 2, Pages (February 2009)
Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells  Shomyseh Sanjabi, Munir M. Mosaheb, Richard A.
Volume 29, Issue 5, Pages (November 2008)
Volume 27, Issue 3, Pages (September 2007)
Volume 15, Issue 2, Pages (August 2001)
Volume 31, Issue 4, Pages (October 2009)
Volume 16, Issue 4, Pages (April 2002)
Volume 11, Issue 2, Pages (August 1999)
CD44 Regulates Survival and Memory Development in Th1 Cells
Volume 14, Issue 5, Pages (May 2001)
Susan M. Kaech, Scott Hemby, Ellen Kersh, Rafi Ahmed  Cell 
Antigen-Specific Suppression of a Primed Immune Response by Dendritic Cells Mediated by Regulatory T Cells Secreting Interleukin-10  Ela Martin, Brendan.
Volume 30, Issue 4, Pages (April 2009)
Volume 28, Issue 5, Pages (May 2008)
Volume 32, Issue 1, Pages (January 2010)
Notch 1 Signaling Regulates Peripheral T Cell Activation
The CD28 Signaling Pathway Regulates Glucose Metabolism
Toll-Dependent Control Mechanisms of CD4 T Cell Activation
Luk Van Parijs, Alexander Ibraghimov, Abul K. Abbas  Immunity 
Ovalbumin-specific IgE modulates ovalbumin-specific T-cell response after repetitive oral antigen administration  Nemuko Omata, MD, Yusei Ohshima, MD,
Interleukin-10-Treated Dendritic Cells Modulate Immune Responses of Naive and Sensitized T Cells In Vivo  Gabriele Müller, Anke Müller  Journal of Investigative.
Volume 28, Issue 1, Pages (January 2008)
Dendritic Cells Require T Cells for Functional Maturation In Vivo
Volume 32, Issue 5, Pages (May 2010)
Analysis of Type 2 Immunity In Vivo with a Bicistronic IL-4 Reporter
Epicutaneous Immunization with Autoantigenic Peptides Induces T Suppressor Cells that Prevent Experimental Allergic Encephalomyelitis  Margaret S. Bynoe,
Memory CD8+ T Cells Undergo Peripheral Tolerance
A Key Role of Leptin in the Control of Regulatory T Cell Proliferation
Volume 25, Issue 3, Pages (September 2006)
Volume 20, Issue 6, Pages (June 2004)
Presentation transcript:

CTLA-4 Regulates Induction of Anergy In Vivo Rebecca J. Greenwald, Vassiliki A. Boussiotis, Robert B. Lorsbach, Abul K. Abbas, Arlene H. Sharpe  Immunity  Volume 14, Issue 2, Pages 145-155 (February 2001) DOI: 10.1016/S1074-7613(01)00097-8

Figure 1 DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− T Cells Exhibit a Naive Phenotype and Respond Comparably to Antigen Lymph node cells were harvested from unstimulated DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− mice, CD4+ T cells were purified from cell suspensions, and CD4+ T cells were stained for the DO11.10 TCR with the clonotypic antibody KJ1-26 and CD4 and analyzed by flow cytometry. The percentage of KJ1-26+ CD4+ T cells is indicated on the FACS plot. Purified CD4+ T cells were stained for CD4 and either CD25 or CD62L. The percentages of double-positive cells are indicated (+/+ and −/− denote CTLA-4 genotype). (B) CD4+ T cells from DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− were cultured with OVA323–339 and APCs for 4 days and restimulated for 3 days, then stained for KJ1-26, CD4, and CD25 or CD62L. The histogram plots represent cells gated on the KJ1-26+ CD4+ population (filled histogram is CD25 or CD62L staining; dashed line is isotype-matched control). The results are representative of three experiments with two to three mice per group Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 2 Levels of Proliferation and Effector Cytokines Are Elevated during the Secondary Responses of DO11+ RAG2−/−CTLA-4−/− T Cells to Antigen Stimulation (A–B) DO11+ RAG2−/− (closed circles) (denoted as +/+ to indicate CTLA-4 genotype) or DO11+ RAG2−/−CTLA-4−/−(open squares) (denoted as −/− to indicate CTLA-4 genotype) T cells were purified and cultured with mitomycin-C-treated APCs and OVA323–339 for 4 days. Proliferation was measured by 3[H]thymidine incorporation during the primary response at day 4 (A) and during the secondary response at day 3 (B) at the indicated peptide concentrations. (C) Cytokine secretion was detected by ELISA of culture supernatants in the primary at days 1–4 and in the secondary at days 1–3 after stimulation with 1.0 μg/ml of OVA peptide. Cells cultured in the absence of peptide did not secrete measurable cytokines (data not shown). The error bars represent standard deviations. These results are representative of three experiments Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 3 Activation-Induced Cell Death Is Comparable in DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− T Cells DO11+ RAG2−/− (closed circles) or DO11+ RAG2−/−CTLA-4−/− (open squares) T cells were purified and cultured with mitomycin-C-treated APCs with OVA323–339 (1.0 μg/ml) for 4 days. T cells were rested overnight with IL-2, and viable cells were cultured with IL-2 and varying concentrations of plate-bound anti-CD3 (0–1.0 μg/ml). After 24 hr, cell death was assessed by FACS analysis, which was indicated as propidium iodide incorporation by CD4+ T cells. The error bars represent standard deviations for triplicate samples. The results are representative of three experiments Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 4 Expansion of DO11+ RAG2−/−CTLA-4−/− T Cells Is Greater Than DO11+ RAG2−/− T Cells In Vivo DO11+ RAG2−/− were adoptively transferred into wt recipients and either untreated (naive), immunized subcutaneously with 50 μg OVA323–339 peptide in IFA (primed), or given 300 μg OVA323–339 in PBS intravenously (tolerized). At 4 and 7 days after treatment, draining lymph node cells were harvested, cell suspensions pooled for each group, and CD4+ T cells purified. A portion of the CD4+ T cells were stained with KJ1-26 and CD4 to measure antigen-specific T cell expansion in vivo and analyzed by flow cytometry. One representative experiment of three, using three to five mice per treatment group, is shown. The percentage of KJ1-26+ CD4+ T cells is indicated on the FACS plots. (Mean percent expansion of KJ1-26+ CD4+ T cells in vivo. [Day 4] DO11+ RAG2−/−: naive = 0.53 ± 0.05, primed = 6.2 ± 1.2, and tolerized = 3.9 ± 0.92; DO11+ RAG2−/−CTLA-4−/−: naive = 0.57 ± 0.17, primed = 14 ± 5.1, and tolerized = 8.6 ± 0.57. [Day 7] DO11+ RAG2−/−: naive = 0.38 ± 0.13, primed = 9.0 ± 0.81, and tolerized = 1.1 ± 0.36; DO11+ RAG2−/−CTLA-4−/−: naive = 0.55 ± 0.05, primed = 12.75 ± 1.55, and tolerized = 2.61 ± 0.21.) The mean and standard deviations represent the average values for three experiments Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 5 DO11+ RAG2−/−CTLA-4−/− T Cells Are Resistant to Tolerance Induction In Vivo DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− were adoptively transferred and treated (naive, primed, and tolerized) 1 day later. Lymph nodes were harvested at days 4 and 7 after treatment. KJ1-26+ CD4+ T cells were cultured with wild-type mitomycin-C-treated APCs and OVA323–339 peptide. Proliferation was measured at day 3 of restimulation for DO11+ RAG2−/− (closed circles) or DO11+ RAG2−/−CTLA-4−/− (open squares) over a range of peptide doses (0–1.0 μg/ml). IL-2 production was detected from culture supernatants on days 1–3 for each treatment group restimulated with 1.0 μg/ml of peptide. Each time point reflects the mean of triplicate samples, and error bars represent standard deviations. One representative experiment of three, using three to five mice per treatment group, is shown Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 5 DO11+ RAG2−/−CTLA-4−/− T Cells Are Resistant to Tolerance Induction In Vivo DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− were adoptively transferred and treated (naive, primed, and tolerized) 1 day later. Lymph nodes were harvested at days 4 and 7 after treatment. KJ1-26+ CD4+ T cells were cultured with wild-type mitomycin-C-treated APCs and OVA323–339 peptide. Proliferation was measured at day 3 of restimulation for DO11+ RAG2−/− (closed circles) or DO11+ RAG2−/−CTLA-4−/− (open squares) over a range of peptide doses (0–1.0 μg/ml). IL-2 production was detected from culture supernatants on days 1–3 for each treatment group restimulated with 1.0 μg/ml of peptide. Each time point reflects the mean of triplicate samples, and error bars represent standard deviations. One representative experiment of three, using three to five mice per treatment group, is shown Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 6 Cell Cycling Is Greater in DO11+ RAG2−/−CTLA-4−/− T Cells Given a Tolerogenic Stimulus In Vivo Division of CFSE-labeled DO11+ RAG2−/− (solid line) or DO11+ RAG2−/−CTLA-4−/− (dashed line) T cells after adoptive transfer into wt recipients. At day 3 following treatment (naive, primed, or tolerized), draining lymph nodes were collected. Cell suspensions were stained for CD4 and KJ1-26. Histograms represent CFSE expression gated on CD4+ KJ1-26+ T cells. These results are representative of three experiments Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)

Figure 7 DO11+ RAG2−/− but Not DO11+ RAG2−/−CTLA-4−/− T Cells Given a Tolerogenic Stimulus Are Arrested at the G1 Phase of the Cell Cycle (A) Lysates from unstimulated DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− T cells were analyzed by SDS-PAGE and immunoblotted with antiserum specific for p27kip1. Blots were stripped and reprobed with antiserum specific for cdk4 and cdk2. (B) Following adoptive transfer of DO11+ RAG2−/− and DO11+ RAG2−/−CTLA-4−/− T cells and treatment (N, naive; P, primed; or T, tolerized), CD4+ KJ1-26+ T cells were restimulated with mitomycin-C-treated APCs and OVA peptide for 3 days. At day 3, lysates were prepared and analyzed by SDS-PAGE and immunoblotted with antiserum specific for cyclin D2, cdk4, or cdk2. To assay kinase activity, immunoprecipitations were performed with anti-cdk2-specific antiserum, and in vitro kinase reactions were done using histone H1 as exogenous substrate. (C) The same immunoblots used in (B) were stripped and reprobed with monoclonal antibody specific for p27kip1. (D) Lysates from the same samples described above (“unst,” unstimulated), were immunoblotted with monoclonal antibody specific for Rb. Densitometric values are provided on each blot. Results are representative of three experiments Immunity 2001 14, 145-155DOI: (10.1016/S1074-7613(01)00097-8)